Linked Life Data

10993597

Source:http://linkedlifedata.com/resource/pubmed/id/10993597

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2000-10-19
pubmed:abstractText
Fracture incidence is increased in growth hormone deficiency (GHD). However, the efficacy of growth hormone (GH) in the prevention of fractures in GHD is not documented. GH is important to attain normal peak bone mass; it increases bone mass in children and adolescents, but is less important with increasing age and is insignificant above the age of 55-60 years old. Placebo-controlled trials of 12 months' duration have failed to improve bone mass density, while uncontrolled studies have suggested that GH treatment for 2-4 years may increase bone mass by 0.5 of a standard deviation in adults. Given the current high price of GH treatment, however, routine substitution with the intention to decrease fracture incidence in adult GHD patients is not likely to be cost effective. GH substitution should probably be extended until peak bone mass has been achieved, and repeated dual energy X-ray scan measurements with intervals of 1-2 years could be helpful in deciding when to stop treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1096-6374
pubmed:author
pubmed:issnType
Print
pubmed:volume
8 Suppl A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
81-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Does growth hormone therapy in adult patients with growth hormone deficiency protect against bone loss?
pubmed:affiliation
Department of Endocrinology and Metabolism, Aarhus University Hospital, Amtssygehuset, Denmark.
pubmed:publicationType
Journal Article, Review